Will the HTVN 142 clinical trial to vaccinate against HIV be successful?
3
Ṁ70Ṁ86Jan 1
81%
chance
1H
6H
1D
1W
1M
ALL
This question will resolve to YES if the vaccine trial is found to have >= 90% efficacy in preventing new HIV transmission in participants.
Context per NIH:
HVTN 142 is taking place at six sites in the United States and four in South Africa and will enroll 95 HIV-negative participants. Participants will be randomly assigned to one of four study arms: three arms will each receive a different dose of the vaccine, and one will receive a placebo. To optimize participant safety, this study will only enroll people already living with asymptomatic CMV. Initial results are expected in late 2024, and an optional long-term sub-study will continue to follow volunteers for up to three years after their first vaccine dose.
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000People are also trading
Related questions
Will the Phase 3 Trials of Olpasiran be a Success?
60% chance
Will the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
62% chance
Will the M72/AS01E tuberculosis vaccine candidate have an efficacy of 50% or higher in the phase 3 trial?
59% chance
Will a dengue vaccine based on TV003/TV005 be approved before 2050?
61% chance
Will a vaccine for HIV be approved by the FDA and be available for public use by 2027?
28% chance
What will the Danish single-blind HepB vaccine study funded by RFK show?
Will AOH1996 succeed in Phase I trial?
73% chance
Will the Russian cancer vaccine work?
16% chance
Will a vaccine for HIV be a available in the US or Europe by 2030?
47% chance
Will a vaccine for HIV be approved by the FDA by 2030?
74% chance